Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.

ABSTRACT:

Background

Options remain limited for patients requiring later lines of therapy for metastatic non-small cell lung cancer (mNSCLC) due to poor prognosis and potential toxicities. Therefore, trials of novel combinations of existing therapeutic candidates are warranted. Here, we report robust interim analysis results from the MORPHEUS-Lung study in immune checkpoint inhibitor (CPI)-exposed patients with non-squamous mNSCLC and without targetable gene mutations.

Methods

MORPHEUS-Lung enrolled patients with disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 immune CPI, given in combination as one line or as two separate lines of therapy, regardless of PD-L1 expression. The primary efficacy endpoint was objective response rate (O

SUBMITTER: Ghiringhelli F 

PROVIDER: S-EPMC12323520 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature